General Information of Drug (ID: DMTMBEX)

Drug Name
ISIS 102486 Drug Info
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
TTD Drug ID
DMTMBEX

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Patented Agent(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
VFEDEOUBYBLDKN-AAFJCEBUSA-N DMH9ION N. A. N. A. Patented [2]
XHPNYYOUZWOWNT-PYUWXLGESA-N DM5Q93Y N. A. N. A. Patented [2]
AGGGWZCOULSEER-PYUWXLGESA-N DM2L83Y N. A. N. A. Patented [2]
BALANOL DMDLN9E N. A. N. A. Terminated [3]
4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol DMSKJ1X Discovery agent N.A. Investigative [4]
Ro-4396686 DM5DMCH Discovery agent N.A. Investigative [5]
NM-PP1 DMS8H5Q Discovery agent N.A. Investigative [6]
ISIS 102633 DMWT7BK Discovery agent N.A. Investigative [1]
ISIS 102604 DMZ6X9B Discovery agent N.A. Investigative [1]
ISIS 102619 DMXH9IT Discovery agent N.A. Investigative [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
PRKACA messenger RNA (PRKACA mRNA) TT5U49F KAPCA_HUMAN Not Available [1]

References

1 US patent application no. 6,248,586, Antisense modulation of PKA catalytic subunit C-alpha expression.
2 Purine derivatives. US8846696.
3 Joys of molecules. 2. Endeavors in chemical biology and medicinal chemistry. J Med Chem. 2005 Sep 8;48(18):5613-38. Address;
4 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
5 Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3.
6 The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.